BMPR2 and pulmonary arterial hypertension: In 2016, Harper et al. demonstrated that adenoviral gene delivery of BMPR2 inhibited MCT-induced PAH, as illustrated by the reduced RV hypertrophy, RV systolic pressure, mean PAP [152].